

**Red Española para el Desarrollo de  
Métodos Alternativos a la  
experimentación animal**

**10 años**



**1999-2009**

***Los métodos alternativos a la experimentación  
animal ante las nuevas normativas  
internacionales***

**IV Jornada de REMA, X Aniversario  
Colegio Oficial de Veterinarios de Madrid  
1 de diciembre de 2009**

**Documentos disponibles en <http://www.remanet.net/>**

10 años



1999-2009



# REACH

EL VALOR DE LA SEGURIDAD

THE VALUE OF SAFETY

Acceptability of alternative methods


Eugenio Vilanova, Jorge Estévez

Unidad de Toxicología y Seguridad Química  
INSTITUTO DE BIOINGENIERIA  
Universidad Miguel Hernández de Elche

## ¿Why we need a Regulation internationally accepted.

To guarantee

- the safety and confidence of citizens
- free circulations of goods



Clasificación and labelling of dangerous substances


<b>Sustancias nuevas</b>	<b>New chemicals</b>	<b>EC Directiva 67/548/EEC</b>
Datos requeridos	Data requirement	Directiva 92/32/EEC
Criterios de evaluación	Principles	Directva 93/67/EEC
Guias técnicas	Technical Guidance Documents	TGD, EC, 1993

**(30 adaptations)**  
**Methods of testing**

Not in he inventory of Existing substances (EINECS) antes de Sept de 1981

Evaluation on the basis of data required to be presented by the Notifier

<b>Sustancias existentes</b>	Existing chemicals	EC Reg. Consejo 793/93
Principios de evaluación	Risk assesment principles	EC Reg 1488/94
TGDs	TGDs	TGDs for EC Reg 1488/94
TGDs para armonización criterios de evaluación de sustancias Nuevas y Existentes.	TGDs package for harmonization of the evaluation of News and Existing Chemicals	TGDs EC, 1996




Las que estaban en el inventario europeo de sustancias existentes (EINECS) antes de Sept de 1981 (**100.106**)

# EXISTING SUBSTANCES

**A challenge for the evaluation of substances**

Guarantee of safety for human health and the environment



**Industria submit existing data**  
**Competente Authority: responsibility of evaluation (the charge of the proof)**

White Book  
(2001)

**REACH  
Regulation  
(2007)**

**Charge of the proof on industry  
(Estudies and risk  
assessment)**

## Substances with specific regulations

<i>Nombre</i>	<i>Name</i>	<i>Reference</i>
<b>Directiva de Plaguicidas</b>	Directive of Pesticides (or PPP Directive)	EC Dir 91/414/EEC
<b>Medicamentos veterinarios</b>	Veterinary drugs	EC Reg 2377/90
<b>Aditivo alimentarios</b>	Feed additives	EC Dir 70/524/EEC
<b>Aditivos de alimentos</b>	Food additives	89/107/EEC
<b>Cosméticos</b>	Cometics	SCP/803/90
<b>Materiales de embalaje</b>	Packaging materials	EC Dir CSIPM/1025
<b>Biocidas</b>	Biocides	EC Dir 98/8/EEC
TGDs		

**Notifier submitting a dossier with proposed evaluation**

# REACH?

- **Registration, Evaluation, Authorization and Restriction of Chemicals.**
  - **Directive 121/2006 (modify Dir. 67/548 for adapting to REACH)**
  - **Regulation 1907/2006 (direct executive consequence in all EU)**
  - **Technical guides**
- 1 June 2007. (Pre-register until dic 2008)
- REACH gives higher responsibility to industry



# Objectives:

- Protect human health en environment
- Registering about **30.000 substances**
- Increase competitiveness
- Free circulation of substances
- **Industry higher responsibility**
- Communication commercial chain
- **Safe use of chemicals**
- Development of new technologies  
Use of **alternative methods of animal testing**
- transparency

# Procesos de la normativa REACH

- **ECHA:** European Chemical Agency  
(1 June 2007)
- **PRERREGISTER:** Prerregistro de sustancias susceptibles de registro.
- **SHARING DATA (Forum)**
- **REGISTER**
- **EVALUATION**
- **AUTORIZATION**
- **RESTRICTION**

**CLASIFICACION ,  
LABELLING AND  
PACKAGE (CLP)  
(Reg. 1272/2008)**

## Agencia Europea de Sustancias y Preparados Químicos

- Controlará todos los procesos relacionados con la normativa REACH.
- 1 de junio de 2007
- Comités
  - Comité de Evaluación de Riesgos (RAC) – expertos
  - Comité socioeconómico (SEC) -expertos
  - Comité de Autoridades competentes –representación estados

# PRERREGISTRO

- Periodo: **1 junio 2008** → 1 diciembre 2008.

Press Release. Helsinki, 19 December 2008

## LIST OF PRE-REGISTERED SUBSTANCES PUBLISHED

Today, ECHA has published on its website [a list of pre-registered substances](#).

• **2.75 million preregistrations**,

• **by 65,000 companies**

• **about 150,000 substances**

• **between 1 June and 1 December 2008.**

• **cover all the EU “existing substances” (EINECS) and the list of notified new substances (ELINCS), together**

• **about 105,000 substances.**

Helsinki, 27 March 2009

ECHA PUBLISHES AN UPDATED LIST


around **143 000 substances of them**, pre-registered by **some 65 000 companies..**

ECHA does not expect all of these substances to be registered.


## Active Lead Registrants

# Substance Information Exchange Forum (SIEF)

Date	Formed SIEF
<b>25/11/2009</b>	<b>2051</b>
18/11/2009	2025
11/11/2009	2004
03/11/2009	1974
28/10/2009	1928
21/10/2009	1893
14/10/2009	1834
07/10/2009	1793
September 2009	1766
August 2009	1327
July 2009	982
June 2009	574
May 2009	293
April 2009	57



# Registration deadlines



## ESTUDIOS TOXICOLÓGICOS Y METABÓLICOS

**Toxicidad aguda** (Oral. Dérmica. Por inhalación. Irritación cutánea y ocular Sensibilización dérmica.

**Estudios metabólicos en mamíferos.**

**Toxicidad a corto plazo, dosis repetida (28 días)** (oral, dérmica, inhalacion)

**Toxicidad subcrónica** (2 especies)

**Toxicidad crónica**

**Estudios de mutagenicidad** (in vitro, in vivo)

**Estudio de carcinogenicidad**

**Toxicidad para reproducción**(teratogenicidad, fertilidad)

**Datos adicionales** (neurotoxicidad, mecanismos; otras rutas parentales

**Datos en humanos**

## ANNEX VI INFORMATION REQUIREMENTS

### STEP 1 – GATHER AND SHARE EXISTING INFORMATION

The registrant should gather all existing available test data  
... test data to be shared, thereby avoiding unnecessary testing...  
... from (Q)SARs, read-across from other substances, ...

### STEP 2 – CONSIDER INFORMATION NEEDS

### STEP 3 – IDENTIFY INFORMATION GAPS

### STEP 4 – GENERATE NEW DATA/PROPOSE TESTING STRATEGY

... new data shall be generated (Annexes VII and VIII),  
or a **testing strategy shall be proposed** (Annexes IX and X),

**New tests on vertebrates shall only be conducted or proposed as a last resort** when all other data sources have been exhausted.



Tonelaje:	[1,10]	[10,100]	[100,1000]	?1000
-----------	--------	----------	------------	-------

8.1. IRRITACIÓN O CORROSIÓN CUTÁNEAS				
in vitro corrosión cutánea	X	X	X	X
in vitro irritación cutánea (no si corrosivo)	X	X	X	X
in vivo irritación cutánea (no si corrosivo)		X	X	X

8.2. IRRITACIÓN OCULAR				
in vitro de la irritación ocular	X	X	X	X
In vivo irritación ocular		X	X	X

8.3. Sensibilización cutánea				
Ensayo in vivo.	X	X	X	X

8.4. Mutagenicidad				
Estudio in vitro de la mutación génica en bacterias	X	X	X	X
Si 1+ => nuevos estudios de mutagenicidad	X	X	X	X
in vitro citogenicidad en células de mamífero o in vitro ensayo micronucleico.		X	X	X
Si “-“ => in vitro mutación génica en células de mamífero Si “+” considerar ensayos in vivo		X	X	X

8.5. Toxicidad aguda				
Por vía oral	X	X	X	X
Por inhalación		X	X	X
Por vía cutánea		X	X	X

Tonelaje:	[1,10]	[10,100]	[100,1000]	?1000
-----------	--------	----------	------------	-------

<b>8.6. Toxicidad por dosis repetidas</b>				
toxicidad por dosis repetidas a <b>corto plazo (28 días)</b> , [1 especie, vía según exposición] [salvo ensayo a 90 días]		X	X	X
<b>toxicidad subcrónica (90 días)</b> , de una especie, roedores, [vía según exposición]			X	X
<b>a largo plazo (&gt;1 año)</b> [podrá proponerse según exposición]				¿?

<b>8.7. Toxicidad para la reproducción</b>				
<b>toxicidad para el desarrollo</b> , de una especie [Para 10-100, solo si no pruebas por (Q)SAR o in vitro de tóxica para el desarrollo].		X	X	X
<b>toxicidad para la reproducción dos generaciones</b> , [Si no carcinógena genotóxica o mutagénica células germ.] [Para 100-1000 ton, solo si no hay efecto en órganos reproductores a 28 o 90 días]			X	X

<b>8.8 Toxicocinética</b>				
alcance dependerá de la información pertinente disponible		X	X	X

<b>8.9.1. Estudio de carcinogenicidad</b>				
				X

## Example of data required (Subchronic toxicity)

COLUMN 1 STANDARD INFORMATION REQUIRED	COLUMN 2 SPECIFIC RULES FOR ADAPTATION FROM COLUMN 1
<p><b>8.6.2. Sub-chronic toxicity study (90 days)</b>, one species, rodent, male and female, most appropriate route of administration, having regard to the likely route of human exposure.</p>	<p>8.6.2. The sub-chronic toxicity study (90 days) <b>does not need to be conducted if:</b></p> <ul style="list-style-type: none"> <li>– a reliable short-term toxicity study (28 days) is available showing severe toxicity effects according to the criteria for classifying the substance as R48, for which the observed NOAEL-28 days, with the application of an appropriate uncertainty factor, allows the extrapolation towards the NOAEL-90 days for the same route of exposure; or</li> <li>– a reliable chronic toxicity study is available, provided that an appropriate species and route of administration were used; or</li> <li>– a substance undergoes immediate disintegration and there are sufficient data on the cleavage products (both for systemic effects and effects at the site of uptake); or</li> <li>– the substance is unreactive, insoluble and not inhalable and there is no evidence of absorption and no evidence of toxicity in a 28-day "limit test", particularly if such a pattern is coupled with limited human exposure.</li> </ul>

## EJEMPLO DATOS REQUERIDOS

COLUMN 1 STANDARD INFORMATION REQUIRED	COLUMN 2 SPECIFIC RULES FOR ADAPTATION FROM COLUMN 1
<p>8.9.1. Carcinogenicity study</p>	<p><b>8.9.1. A carcinogenicity study <u>may be proposed</u></b> by the registrant or may be required by the Agency in accordance with Articles 40 or 41 if:</p> <ul style="list-style-type: none"> <li>– the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure; and</li> <li>– the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions.</li> </ul> <p><b>If the substances is classified as mutagen category 1 or 2, the default presumption would be that a genotoxic mechanism for carcinogenicity is likely. In these cases, a carcinogenicity test will normally not be required.</b></p>

# SHARING DATA

- Pre-registrants can find other pre-registrants of the same substance for sharing data
  - Pre-registrants of the same substance are obliged to sharing data (paying rights) of existing studies in vertebrates
  - Forum (SIEF) (Substance Information Exchange Forum)



## TITLE III

### DATA SHARING AND AVOIDANCE OF UNNECESSARY TESTING

#### Article 25

##### Objectives and general rules

1. In order to avoid animal testing, **testing on vertebrate animals** for the purposes of this Regulation shall be undertaken **only as a last resort**. It is also necessary to take measures limiting duplication of other tests.

2.....

#### Art 26.3

1. If the same substance has previously been registered **less than 12 years** earlier, the Agency shall inform the potential registrant ....

**2. Studies involving vertebrate animals shall not be repeated.**

## Initial calendar

## REACH

**Table 1.1: The proposed schedule for the registration of 30,100 existing substances (6)**

<b>Number of substances</b>	<b>Volume (tonnes per annum)</b>	<b>Deadline for registration</b>
2600	>1000	end of 2005
2900	100–1000	end of 2008
4600	10–100	end of 2012
20,000	1–10	end of 2012

# ALTERNATIVE METHODS. ACCEPTABILITY OF RESULTS ?

- No guideline but scientifically valid studies?
- **In vitro alternative** validated methods?
- **In vitro non validated** but scientifically valid methods?
- Further development of QSAR, read across (USE OF DATA ACCUMULATED IN ECHA BY REGISTRATION?)



## WHO WILL PARTICIPATE IN DECISIONS PROCESS?

- Experts in staff of ECHA
- Expert in committees
- Competent authorities

## NEED for INCREASING ACCEPTABILITY !!

- Promoting Research
- Interaction among European Institutions (ECHA-ECVAM, Other committees)
- Interaction of European Institution with Academia, Industry, Society, National administrations
- **Role of Consensus Platforms at national and international levels (REMA, ECOPA)**

*VILLENA 8:45 PM*



# GRACIAS POR SU ATENCIÓN

